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Background: In assisted reproduction cycles, gonadotropins are administered to obtain a greater number of
oocytes. A majority of patients do not have an adverse response; however, approximately 3-6% develop ovarian
hyperstimulation syndrome (OHSS). Metformin reduces the risk of OHSS but little is known about the possible
effects and mechanisms of action involved.
Objective: To evaluate whether metformin attenuates some of the ovarian adverse effects caused by OHSS and to
study the mechanisms involved.
Material and methods: A rat OHSS model was used to investigate the effects of metformin administration.
Ovarian histology and follicle counting were performed in ovarian sections stained with Masson trichrome. Vascular
permeability was measured by the release of intravenously injected Evans Blue dye (EB). VEGF levels were measured
by commercially immunosorbent assay kit. COX-2 protein expression was evaluated by western blot and NOS levels
were analyses by immunohistochemistry.
Results: Animals of the OHSS group showed similar physiopathology characteristics to the human syndrome:
increased body weight, elevated progesterone and estradiol levels (P<0.001), increased number of corpora lutea
(P<0.001), higher ovarian VEGF levels and vascular permeability (P<0.001 and P<0.01); and treatment with
metformin prevented this effect (OHSS+M group; P<0.05). The vasoactive factors: COX-2 and NOS were increased in
the ovaries of the OHSS group (P<0.05 and P<0.01) and metformin normalized their expression (P<0.05); suggesting
that metformin has a role preventing the increased in vascular permeability caused by the syndrome.
Conclusion: Metformin has a beneficial effect preventing OHSS by reducing the increase in: body weight,
circulating progesterone and estradiol and vascular permeability. These effects of metformin are mediated by
inhibiting the increased of the vasoactive molecules: VEGF, COX-2 and partially NOS. Molecules that are increased in
OHSS and are responsible for a variety of the symptoms related to OHSS.* Correspondence: danteagustin.paz@gmail.com
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In assisted reproduction cycles, gonadotropins are admin-
istered to obtain a greater number of oocytes. A majority
of patients do not have an adverse response; however, ap-
proximately 3-6% develop ovarian hyperstimulation syn-
drome (OHSS), which is characterized by a variety of
manifestations including ascites, pleural hemorrhage,
hemoconcentration and oliguria. In the severe OHSS, a
form of thromboembolism can occur, and without medical
care, it may lead to death [1,2].
The main characteristic of these manifestations is an
increase in vascular permeability caused by the release
of hCG mediators; however, this mechanism is not fully
understood. Among the wide variety of angiogenic and
vasoactive molecules, vascular endothelial growth factor
(VEGF) plays a preponderant role. The production of
VEGF in endothelial cells is increased by treatment with
hCG, and in turn, the growth factor increases vascular
permeability [1]. In the ovary, VEGF is produced in teca
and granulose cells. There have been reports showing a
relationship between serum VEGF levels and the admin-
istration of hCG, suggesting that it can be used as an
OHSS predictor [2-4]. Moreover, Gomez et al. has sug-
gested that targeting VEGF and its receptor was an ef-
fective preventive approach to treat the syndrome [5,6].
In the mouse skin, Fujii et al. have described that the
vascular permeability induced by VEGF is mediated by
the local production of nitric oxide (NO) and arachi-
donic acid metabolites, which are mainly produced by
NO synthase (NOS) and cyclooxygenase type 2 (COX-2),
respectively [7].
We have previously demonstrated that a beneficial ef-
fect of meloxicam (a COX-2 inhibitor) in OHSS is the
reduction of ovarian weight and VEGF expression in a
rat model of OHSS (Quintana et al., 2008). However,
the administration of meloxicam during in vitro ferti-
lization procedures is not recommended because it
blocks ovulation by inhibiting the breakdown of mature
ovarian follicles [8,9].
Metformin (N,N-dimethylbiguanide) is one of the
most common drugs used for the treatment of type 2
diabetes. Among the various actions of metformin are
its effect activating the adenosine 3’5’-monophosphate
(AMP) dependent kinase alpha (AMPK-a) pathway, de-
creasing the glucose production, increasing fatty acid
oxidation and promoting the uptake of glucose in cells
[10-13]. In polycystic ovary syndrome (PCOS), metfor-
min decreases androgen levels, improves the frequency
of ovulation and menstrual cycles, normalizes uterine
homeostasis and prevents miscarriages [14-17]. Metfor-
min administration also increases the embryo quality,
the clinical pregnancy rate as well as the implantation
rate [18], and it is important to highlight that the mech-
anism of action of metformin involves the modulationof NOS and COX-2 expression in the ovary and the
uterus [19-21].
In contrast, it has been demonstrated that PCOS pa-
tients undergoing fertility treatment who receive gonad-
otrophins have an increased risk for OHSS. Whereas,
when those women were treated with metformin, the
risk of OHSS was reduced [22]. However, little is known
about the possible effects and mechanisms by which
metformin reduces the risk of OHSS.
In view of these findings, metformin appears to be an
alternative treatment for the prevention of OHSS; how-
ever, there are no reports that take in consideration the
mechanisms by which metformin regulates ovarian
physiology in OHSS. Therefore, the purpose of this
study is to evaluate whether metformin attenuates some
of the ovarian adverse effects in OHSS in an animal
model and to study the mechanisms involved.
Materials and methods
Study design
Immature female Wistar rats were obtained from Bioterio
Central, Facultad de Ciencias Exactas y Naturales, UBA.
All research animals were treated in compliance with the
guidelines for the care and use of animals approved by our
institutions in accordance with the principles of laboratory
animal care (NIH Guide for the Care and Use of Labora-
tory Animals, Institute of Laboratory Animal Resources,
National Research Council, Washington, D.C.). Rats were
fed with a standard diet, allowed free access to water, and
had a 12-hour light cycle (lights-on 7AM to 7PM).
Thirty female rats (weight: 44–50 g) were divided into
three groups: (1) the control group (n=10), which re-
ceived 10 IU of pregnant mare serum gonadotropin
(PMSG; Sigma Chemical Co) on the 39th day and 10 IU
of hCG (Sigma) 48 hours later (day 41) to mimic routine
ovarian stimulation; (2) the OSSH group (n=10), which
received 50 IU of PMSG daily from days 37 to 40 and
30 IU hCG on day 41 to induce OHSS; (3) the OHSS+
MET group (n=10), which underwent the same hormo-
nal stimulation protocol as the OHSS group in addition
to treatment with metformin (Boehringer, Buenos Aires,
Argentina) (50 mg/kg body weight) for 20 consecutive
from days 22 to 41. The OHSS animal model has been
first described by Ujioka et al. [23] and later used by
other authors including our group [4,24-26], showing
that this model shows the main characteristics of the hu-
man syndrome.
All hormones were intraperitoneally administered, while
metformin was administered orally. The following two
series of experiments were performed 48 h after the
hCG injections. In the first series, both ovaries from five
rats in each group were weighed and then homogenized
for immunoblot analysis and VEGF level measurement.
The blood was used for hormone assays and VEGF level
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ovary from five rats in each group was used to measure
ovarian vascular permeability with Evans Blue (EB), and
the other was used for immunohistochemistry and fol-
licular counting.
Evaluation of vascular permeability
Vascular permeability was measured by monitoring the
release of intravenously injected Evans Blue dye (EB)
into the peritoneal fluid and ovarian tissue as previously
described [24,27]. Briefly, 48 hours after hCG adminis-
tration, 5 mM EB dye was diluted in distilled water and
0.2 ml was intravenously (i.v.) injected with an insulin
injector through the tail vein. After a 30-min waiting
period, all rats were weighed and intramuscularly adminis-
tered 40/4 mg/kg ketamine (Ketafine; Brouwer, Argentina) /
xilacine (Xylacine; Alfasan Woerden-Holland, Holland).
Then, the peritoneal cavity was filled with 5 ml 0.9% NaCl
solution and massaged for 30 seconds, and subsequently,
the fluid was gently extracted from the abdominal cavity
to prevent tissue or vessel damage. Protein interference
was avoided by recovering the peritoneal fluid in tubes
containing 0.05 ml 0.1 N NaOH. Fluid was clarified by
centrifugation at 900 × g for 12 min, and then it was used
to determine the EB concentration in the recovered fluid.
Then, euthanasia was performed, and the ovaries were
removed. One ovary was removed and fixed in % (w/v)
formaldehyde, and the other ovary was incubated in
2 ml of formamide for 24 hsh at 37°C.
The EB concentration in the formamide extract and in
peritoneal fluid was measured as a function of light ab-
sorption at 600 nm, which was determined using a spec-
trophotometer. The EB concentration was expressed as
micrograms per mL of the peritoneal fluid, and the
ovarian EB content was expressed as nanograms per
milligram tissue wet weight.
Hormone assays
Serum estradiol levels were measured using an electroche-
miluminescene immunoassay (ECLIA) according to the
manufacturer’s instructions (Elecsys analyzer Roche Diag-
nostics), and serum progesterone levels were measured by
an immunochemiluminescence assay (ICMA). All samples
were measured at the same time to minimize errors. Re-
sults are expressed as nanograms per dL serum for P4,
and for E2, they are expressed as picograms per serum
milliliter.
Immunohistochemistry
Fixed ovarian samples were dehydrated and embedded
in paraffin. Six-micron sections were mounted on
gelatin-coated glass slides, deparaffinized in xylene, hy-
drated through a series of graded alcohols and washed
in phosphate-buffered saline (PBS). The tissue sectionswere treated with 3% hydrogen peroxide (H2O2) to
quench endogenous peroxidase activity. Nonspecific
binding sites were blocked by treating the tissues with
5% (w/v) non-fat milk at room temperature for 30 min
and subsequently incubated with primary antibodies for
24 hours at 4°C in a dark, moist chamber. We used a
rabbit anti-NOS (ab-15203, Abcam, Cambridge, Mass,
USA) antibody. After incubation with primary antibody,
the sections were washed with PBS and treated with the
appropriate biotinylated antibody (Vector Laboratories,
Burlingame, United Kingdom) followed by an avidin-
horseradish peroxidase-biotin complex (Vectastatin
Elite ABC kit; Vector Lab, Burlingame, Calif, USA). The
color reaction was visualized by exposure with the 30,
30-diaminobenzidine tetrahydrochloride DAB staining
kit (Dako Cytomation, Carpinteria, CA, USA). Negative
control sections were performed by omitting primary
antibody. After color development, sections were coun-
terstained with Mayer’s hematoxylin solution (Dako).
Images from a standard light microscope were acquired
with the Cool-SNAP-Pro Color camera system and ana-
lyzed with Image ProPlus 6.2 software (Media Cybernetics,
Bethesda, MD).
Ovarian histology and follicle counting
Ovarian tissue sections were stained with Masson
trichrome stain and used to show the smooth muscle
according to standard protocols and analyzed under a
Zeiss Axiophot light microscope. Six-micron sections
were mounted at 50 μm intervals onto microscope slides
to prevent counting the same structure twice, according
to the method described by Woodruff et al. [28]. Follicles
were classified into three types: Preantral (PFs), antral
(AFs) and preovulatory (POs). In the PFs group we gath-
ered all the follicles that had no antrum, including primor-
dial, primaries and preantral follicles strictly speaking.
Primordial follicles were characterized as oocytes sur-
rounded by a single layer of flattened granulosa cells. Pri-
mary follicles were characterized as oocytes surrounded
by a single layer of cuboidal granulosa cells. Preantral folli-
cles were characterized as oocytes surrounded by two or
more layers of cuboidal granulosa cells with no visible
antrum.
AFs were classified according to the presence of a small
antrum and POs according to the presence of a big central
antrum showing an eccentric oocyte. In addition, the
number of corpora lutea (CL) was counted in each section
analyzed. To assess the ovulation rate in the ovarian tis-
sue, the number of corpora lutea was determined in the
same sections as the other types of follicles. The abun-
dance of each type of follicle was normalized by the total
ovarian area in the section as reported previously [29,30].
The ovary area was measured with Image J (version 1.42q)
and expressed per 10 mm2.
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Ten ovaries from each group were lysed for 20 min at 4°C
in lysis buffer (20 mM Tris–HCl, pH = 8.0, 137 mM NaCl,
1% Nonidet P-40 and 10% glycerol) supplemented with 1
X protease inhibitors cocktail (Sigma). The lysate was
centrifuged at 4°C for 10 min at 10 000 × g, and the pellet
was discarded. Protein concentrations in the supernatant
were measured by Bradford assay (Bio-Rad, Hercules, CA,
USA).
Determination of serum on ovarian VEGF levels
VEGF-A concentration was measured by commercially
available Sandwich Enzyme-Linked Immunosorbent assay
kit for rat VEGF (R & D System, Minneapolis, USA) using
serum and ovarian homogenates. Assay was performed
according to the manufacturer’s instruction. The detection
sensitivity range of the kit was 30–2000 pgml−1 and
showed no cross-reactivity with a series of soluble
immunoactive molecules with a good reproducibility.
The coefficient of variation was less than 9.5%. Results
are expressed as pg/mg of tissue wet weight or pg/mL
peritoneal fluid.
Western blot
After boiling for 5 min the ovarian lysates, 90 μg of protein
from each sample was applied to an SDS-polyacrylamide
gel (10%) and electrophoresis was performed at 100 V for
1.5 h. The separated proteins were transferred onto PDVF
membranes in transfer buffer (20% methanol, vol/vol;
0.19 M glycine; 0.025 M Tris-Base, pH = 8.3) for 1 h at 4°C.
Blots were blocked for 1.5 h in TBS (4 mM Tris–HCl,
pH = 7.5, 100 mM NaCl) containing bovine serum albu-
min (0.1%) at room temperature. Rabbit polyclonal anti-
COX2 (1:500, overnight). Santa Cruz Biotechnology Inc.,
USA) and Glyceraldehyde-3-PDH (GADPH) (Millipore,
USA) were used as primary antibodies. Rainbow-colored
protein mass markers (14.3–200 kDa, Bio-Rad) were
applied to determine the bands of COX2 (72 kDa) and
GADPH (38 kDa). Protein bands were visualized by incu-
bating the blots with biotin-conjugated secondary anti-
rabbit IgG (1:2000, 1 h) followed by streptavidin–peroxidase
complex and diaminobenzidine solution. Consistency ofTable 1 Body weight and endocrine characteristics of control
Control
Body weight (g) 149,2 ± 1,0
Ovarian weight (mg) 63,2 ± 2,4
Uterine weight (mg) 231,6 ± 15,3
Progesterone (ng/dL) 188,7 ± 26,3
Estradiol (pg/mL) 36,3 ± 0,7
n 10
Values are expressed as mean ± S.E.M and the P values were determined by one w
to control group; # P<0,05 respect to the OSSH group.protein loading was evaluated by staining the membranes
with Ponceau-S and relative to the GADPH protein levels.
The intensities (area × density) of the individual bands on
western blots were quantified by densitometry (Model
GS-700, Imaging Densitometer, Bio-Rad). The experiment
was independently repeated three times. Results are
expressed in arbitrary units.
Statistical analysis
Results are expressed as mean ± SEM. Comparisons be-
tween groups were performed using either one-way
ANOVA in conjunction with Tukey’s test or Student’s
t-test, where appropriate. The statistical level of signifi-
cance was defined as P < 0.05.
Results
Measurement of body, ovarian and uterine weight and
serum hormone levels
The effects of hyperstimulation and metformin on the
body, ovarian and uterine weight and serum estradiol
and progesterone are summarized in Table 1. Body weights
were increased in hyperstimulated animals (OHSS group)
with respect to control rats (p<0.001), and pretreatment
with metformin (OHSS+MET) prevented this effect. The
ovarian and uterine weights of the OHSS rats were
greater than the control rats (p<0.001 and 0.05, respect-
ively), while treatment with metformin did not modify
these parameters.
The progesterone and estradiol levels were greater in
OHSS rats compared with control animals (p<0.001),
and metformin prevented the increase in estradiol levels.
Ovarian morphology
To study the effects caused by metformin on ovarian
morphology in the OHSS rat model, ovarian tissue sec-
tions were stained to determine the number of follicles
in follicle stages (Figure 1). In the OHSS group, the
number of preantral, antral and preovulatory follicles
were significantly lower than that in the control group,
while the number of CLs were higher in the OHSS
group. Metformin significantly increased the number of
preantral and antral follicles in treated compared withand hyperstimulated animals
OHSS OHSS + M
167,8 ± 3,1*** 156,2 ± 3,9#
224,0 ± 13,1*** 233,3 ± 15,4***
322,6 ± 21,9* 362,5 ± 29,9**
1035 ± 122,9*** 751,1 ± 115,7**
166,3 ± 23,0*** 98,5 ± 22,3#
10 10
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Figure 1 Effect of the treatment with Metformin on the ovarian
morphology in an OHSS rat model. This is a quantitative
morphometric analysis of the ovarian sections after Masson
trichrome staining. Follicles were classified according to the stage of
development indicated in materials and methods. Values are
expressed as the number of follicles per 10 mm2. Data represent the
mean ± S.E.M for 10 ovaries from different animals with the same
treatment, and each value represents the mean of 10 sections from
the same ovary. ** P< 0.01 and *** P< 0.001 respect to the control
group; # P< 0.05 between the pointed groups.
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metformin normalized the number of CLs.
Effects of OHSS and metformin on vascular permeability
We were interested in evaluating the effects of treatment
on vascular permeability because this is the main charac-
teristic of the syndrome, and it is unknown whether
metformin is able to prevent the increase in the capillary
permeability. In our results, the ovarian EB content was
significantly higher in hyperstimulated rats than control
animals (p<0.01), indicating a significant increase in vas-
cular permeability in this group; this effect was partially
prevented by pre-treatment with metformin (OHSS vs.
OHSS+MET, p<0.05) (Figure 2). The same effect wasCtr
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Figure 2 Vascular permeability measured as concentration of
Evans Blue (EB) in ovaries homogenates and in peritoneal fluid.
Each bar represents the mean ± S.E.M and the P values were
determined by one way ANOVA, followed by Tukey’s test. * P< 0.05,
** P< 0.01 and *** P< 0.001 respect to the control group; # P< 0.05
between the pointed groups.observed when we analyzed the peritoneal fluid EB con-
tent, where we found an increase in peritoneal fluid EB
content in hyperstimulated rats (p< 0.001) that was par-
tially prevented by pretreatment with metformin (OHSS
vs. OHSS+MET, p<0.05).
Effect of OHSS and metformin on VEGF levels
Because VEGF is the main factor involved in the path-
ology of OHSS, the level of this glycoprotein was mea-
sured in peripheral serum and the ovaries.
The ovarian VEGF concentration was significantly in-
creased in the OHSS group with respect to the control
group (p<0.001), and metformin partially reduced the
VEGF concentration in treated compared with untreated
OHSS rats (OHSS vs. OHSS+MET, p<0.05).
The serum VEGF concentration measured in OHSS rats
showed an important increased in comparison with con-
trols (p<0.001), but metformin administration did not
show significant changes in this parameter (Figure 3).
Ovarian cyclooxygenase protein expression
COX-2 is another important angiogenic factor that acts
through VEGF that is one of the most important pro-
teins involved in ovulation. Thus, because we are indu-
cing ovulation and found that the VEGF levels are
altered after treatment, we decided to evaluate the ovar-
ian COX-2 protein expression. We found an increase in
COX-2 ovarian levels in OHSS rats (p<0.05) that was
prevented when the animals received pretreatment with
metformin (OHSS vs. OHSS+MET, p<0.05) (Figure 4).
NOS protein localization
The results of immunohistochemical analysis revealed
moderate NOS staining in theca,granulose cells and oocytes
from developed follicles in all groups analyzed.Ctr
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Figure 3 Concentration of the vascular endotelial growth factor
(VEGF) in ovaries homogenates and in serum. Each bar
represents the mean ± S.E.M and the P values were determined by
one way ANOVA, followed by Tukey’s test. *** P< 0.001 respect to
the control group and # P< 0.05 between the pointed groups.
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Figure 4 Protein expression of Cycooxygenase type 2 (COX-2)
in the ovaries. Each bar represents the mean ± S.E.M and the P
values were determined by one way ANOVA, followed by Tukey’s
test. * P< 0.05 respect to the control group and # P< 0.05 between
the pointed groups.
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immunoreactivity in the corpus luteum (CL) when com-
pared with CLs from the control group (p<0.01). In the
OHSS+MET treatment group, NOS immunoreactivity
was diminished in CLs when compared with those in
the OHSS group (p<0.0001) (Figure 5), suggesting that
metformin affects NOS protein expression.
Discussion
Preventing OHSS remains a challenge for in vitro fer-
tilization. Several strategies have been proposed for
preventing the development of OHSS [31-38] as well as
some drugs, such as oral contraceptives, leuprolide acet-
ate, metformin, dexamethasone, low-dose aspirin and
dopamine agonists. These drugs have been proven to be
safe for other uses and are highly effective adjuncts for
ovarian stimulation in “orphan” indications [39]. In par-
ticular, metformin administration has been confirmed to
be a safe and effective strategy for reducing the inci-
dence of OHSS [37]. Recently, it has been clinically dem-
onstrated that it has been specified from a clinical point
of view that metformin administration decreases the risk
of moderate/severe OHSS by 80% and the risk of
hospitalization by 75% [22]. Furthermore, patients with
PCOS who are subfertile receive gonadotrophins while
being treated with metformin to reduce the risk ofOHSS [40]. However, at present,metformin specific effects
and mechanisms of action are still unknown.
In the results of this study, we found an increase in
the number of CLs in the OHSS group showing an
increase in the induced ovulation rate (Figure 1). This
effect was found concomitantly with a reduction in the
number of preantral, antral and preovulatory follicles,
suggesting that hormonal administration induced ovula-
tion without inducing early follicular development. In
addition, treatment with metformin prevented the effects
of hormonal administration because the number of CLs
was normalized in the OHSS+M group, indicating that
metformin acts by decreasing the ovulation rate. The
fact that metformin normalized the ovulation rate and
number of preantral and antral follicles suggests that
metformin was capable of affecting early folliculogenesis
and ovulation. This result is in concordance with the
that described by De Leo [41] who found a reduction in
the number of follicles>15 mm in diameter in patients
who received metformin treatment before the induction
of ovulation. This finding indicates a lower incidence of
ovarian overstimulation after metformin administration
and supports the hypothesis that insulin plays a role in
the endocrine and paracrine control of the ovaries [41].
Research suggests that VEGF is responsible for the in-
creased vascular permeability leading to the extravasation
of protein-rich fluid and subsequent OHSS progression
[42,43]. In addition, high levels of VEGF have been
detected in serum and follicular fluids from women with
severe OHSS [44]. Here, we found increased VEGF levels
in the ovaries and serum from rats with induced OHSS.
Moreover, in this OHSS group, we detected one of the
main characteristics of the syndrome: increased vascular
permeability, which was demonstrated by the increased
level of Evans Blue dye detected in different organs. In our
results, this increased permeability was reduced with the
metformin treatment (Figure 2). The increase in vascular
permeability in the OHSS animals may be caused by the
high levels of VEGF observed in this group as previously
described [45,46]; however, further experiments are nee-
ded to clarify this point. Furthermore, it has been de-
scribed in another system that metformin prevented the
increased vascular permeability [47]. The fact that metfor-
min prevented the increase in vascular permeability and
the levels of VEGF (Figure 3) suggests that the mechanism
by which metformin normalizes the vascular permeability
may be through VEGF modulation.
In addition to VEGF, cyclooxygenase 2 (COX-2) has
been described as an angiogenic factor in other systems
[48,49]. COX-2 is a key enzyme in the conversion of ara-
chidonic acid to prostaglandins and other eicosanoids.
COX-2 is induced by a variety of factors, including cyto-
kines, growth factors, and tumor promoters, and it is
upregulated in many cancers and has been associated with
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Figure 5 NOS immunoreactivity in control and treated rat ovaries. (A) Representative ovarian sections showing the immunolocalization of
NOS from: upper panel: a control rat; middle panel: a OSSH rat; and lower panel: a OHSS+MET rat. A, C and E shows developed follicles (×100)
while B, D and F (×100) shows corpora lutea. (B) Densitometric analyses of NOS immunoreactivity in the rat ovaries. Each bar represents the
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over, the vascular permeability in mouse skin induced by
VEGF, was mediated by modulation of NOS and COX-2
[7]. Although the importance of COX-2 in the ovulatory
process has been documented, the exact functions of this
prostaglandin in human ovaries, fertilization, and implant-
ation are not completely understood [43].
In our results, we found an increase in the ovarian
COX-2 expression in the OHSS group concomitantlywith an increase in ovarian NOS levels. Our findings
agree with previous reports that showed an increase in
ovarian COX-2 expression in a mild OHSS condition [4]
and suggest that, in our model, VEGF may be acting
through COX-2 and NOS in the ovary.
In contrast, we found that metformin restored vascular
permeability and normalized the COX-2 and the VEGF
ovarian levels. The effect of metformin in preventing the
increase in ovarian COX-2 expression has also been
Elia et al. Journal of Ovarian Research 2013, 6:62 Page 8 of 9
http://www.ovarianresearch.com/content/6/1/62observed in an animal model of PCOS [19]. Moreover,
the effect of metformin in decreasing VEGF levels has
been also described in other systems [51,52]. Taking into
account these findings, we suggest that, in our model,
metformin was able to normalize vascular permeability
by normalizing the VEGF abundance and may be acting
through COX-2 and NOS. An important regulator of
these angiogenic molecules is hypoxia-inducible factor-1
(HIF-1). This transcriptional complex is expressed in rat
ovarian granulosa cells in response to hCG treatment,
and the inhibition of HIF-1 inhibits ovulation in rats
[53]. HIF-1 increases the transcription of several genes
to produce proteins that promote blood flow and inflam-
mation including VEGF, NOS and COX-2 [54].
Further studies are being designed to clarify whether
metformin normalizes vascular capillarity directly by af-
fecting ovarian COX-2 and VEGF abundance or if met-
formin only decreases ovarian COX-2 levels, whether
this protein normalizes vascular capillarity by regulating
VEGF levels, and to elucidate whether HIF-1 is involved
in this interplay.
In conclusion, our results demonstrate that metformin
has a beneficial effect on OHSS by reducing increasing
body weight, circulating progesterone and estradiol and
vascular permeability. These effects are mediated by a
metformin-mediated inhibition of the vasoactive mole-
cules VEGF, COX-2 and partially NOS, which are mole-
cules increased in OHSS and responsible for a variety of
symptoms related to OHSS.
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